Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

171.09 +3.84 (+2.30%)
Official Closing Price Updated: 7:00 PM EDT, Sep 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Glaukos Corporation Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Glaukos Announces Participation in Stifel Healthcare Conference
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Third Quarter 2023 Financial Results
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Academy of Ophthalmology Annual Meeting
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release Third Quarter 2023 Financial Results after Market Close on November 1, 2023
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in Wells Fargo Healthcare Conference
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Second Quarter 2023 Financial Results
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Enters into a Collaboration and Marketing Agreement with Radius XR, Inc.
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release Second Quarter 2023 Financial Results after Market Close on August 2, 2023
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Achieves Pipeline Milestone with Enrollment Completion in Phase 3 Confirmatory Trial for Epioxa (Epi-on)
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in the William Blair Growth Stock Conference
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces FDA Acceptance of NDA Submission for iDose TR
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces First Quarter 2023 Financial Results
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Society of Cataract and Refractive Surgery Annual Meeting
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces the Release of its 2022 Sustainability Report
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release First Quarter 2023 Financial Results after Market Close on May 3
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Submits New Drug Application to U.S. FDA for iDose TR
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Fourth Quarter and Full Year 2022 Financial Results
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in the Citi Healthcare Conference
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release Fourth Quarter and Full Year 2022 Financial Results after Market Close on February 22
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerability
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Programs
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in the Stephens Annual Investment Conference
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Corporation Announces Third Quarter 2022 Financial Results
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos to Release Third Quarter 2022 Financial Results after Market Close on November 2
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Academy of Ophthalmology Annual Meeting
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Positive Topline Outcomes for Both Phase 3 Pivotal Trials of iDose TR, Achieving Primary Efficacy Endpoints and Demonstrating Favorable Tolerability and Safety Profiles
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces More Than 1 Million iStent® Technologies Implanted Worldwide
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces Participation in the Wells Fargo Healthcare Conference
From Glaukos Corporation
Via Business Wire
News headline image
Glaukos Announces FDA 510(k) Clearance of iStent infinite®
From Glaukos Corporation
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.